Location: Home > Pharma China Web Edition
  • search
  • go
  • Product/R&D News
  • 11/18/2025Roche's Subcutaneous PD-L1 Therapy Wins China Approval
  • 11/18/2025Sinovac Expands Flu Vaccine Use to Infants from 6 Months
  • 11/18/2025Qilu to Share First-in-Human Data of Trispecific Antibody QLS4131 at A...
  • 11/18/2025Akeso's First CNS Candidate Cleared for Alzheimer's Clinical Trials in...
  • 11/18/2025Henlius and Organon Score First Interchangeable Biosimilar to Perjeta
  • 11/14/2025NMPA Clears IND for GenSci's In-House Bispecific ADC GenSci140
  • 11/13/2025GenFleet Registers First Phase 3 Trial of KRAS G12D Inhibitor GFH375 i...
  • 11/11/2025Zydus Receives China NMPA Approval for Venlafaxine ER Capsules
  • 11/11/2025Glenmark Gains NMPA Approval for RYALTRIS®
  • 11/11/20253SBio Presents Encouraging Phase 2 Results for SSGJ‑707 at SITC 2025
  • 11/11/2025China Approves CPEB's Pediatric CAR‑T Therapy for r/r B‑ALL
  • 11/11/2025Summit and Akeso Report Positive Phase III Results for Ivonescimab at ...
  • 11/11/2025Innovent and SanegeneBio Present Positive Phase 1 Data for siRNA Thera...
  • 11/11/2025Huahui to Present 48-Week Phase 2b Data of Libevitug at AASLD 2025
  • 11/7/2025Lepu to Present Promising Phase II Data of CD20 ADC MRG001 Plus Orelab...
  • 11/7/2025CARsgen Reports Positive Results for Allogeneic CAR-T Therapies CT0596...
  • 11/7/2025Sanofi's Cablivi Wins Approval in China as First Nanobody Therapy for ...
  • 11/7/2025Correctseq Reports World's First Gene-Editing Treatment for Hyperlipid...
  • 11/6/2025China Grants Conditional Approval for ACEA's COVID-19 Antiviral Olgotr...
  • 11/6/2025Novartis Wins China Approval for Two Pluvicto Indications
  • 11/5/2025AbbVie's CD20×CD3 Bispecific Epcoritamab Fails to Win China Approval
  • 11/5/2025Lumosa's Stroke Drug Achieves Phase IIb Success in China
  • 11/5/2025CDE Grants Breakthrough Therapy Designation to Ivonescimab for Triple-...
  • 11/4/2025Huadong Medicine Initiates Phase I Trial of CDH17-Targeting ADC HDM201...
  • 11/4/2025CStone Receives NMPA IND Approval for Phase II Trials of CS2009
  • 11/4/2025Abbisko Begins Phase II Trial of Oral PD-L1 Inhibitor ABSK043 in Combo...
  • 11/4/2025Genscript Secures NMPA IND Clearance for Second Bispecific ADC GenSci1...
  • 10/31/2025Lumosa's Stroke Drug Achieves Phase IIb Success in China
  • 10/31/2025Junshi's Toripalimab Becomes First Immunotherapy Approved for NPC in C...
  • 10/31/2025Sichuan Biokin Advances 11th ADC Candidate BL-M24D1 into Clinical Tria...
  • Page:1/20 Total number of articles:595: [First][<<] [1] [2] [3] [4] [5] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group